Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADvocate2
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 01 Dec 2024 Results of subset pooled anaylsis(ADvocate1, ADvocate2, and ADhere) evaluating 16-week physician- and patient-reported outcomes of lebrikizumab in the adolescent patients, published in the Journal of Dermatological Treatment
    • 25 Oct 2024 According to an Eli lilly media release, EBGLYSS was approved in Japan in January 2024, with additional markets expected later this year.
    • 13 Sep 2024 According to an Eli lilly media release, company announced today the U.S. Food and Drug Administration (FDA) approved EBGLYS (lebrikizumab-lbkz) for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies based on the results of ADvocate 1, ADvocate 2, and ADhere studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top